New dermatology portfolio drives Almirall in first nine months
This article was originally published in Scrip
Almirall's new dermatology portfolio helped drive net sales, which reached €685.2 million in the first nine months of 2009, up by 16% compared with the same period last year. The Spanish company's total revenues grew by 18% to €808.7 million.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.